Original Research7 August 2018
A Prospective Cohort Study
    Author, Article, and Disclosure Information



    Evidence regarding potential adverse neuropsychiatric effects of efavirenz is conflicting, and data from sub-Saharan Africa, where 70% of persons living with HIV (PLHIV) reside and efavirenz is used as first-line therapy, are limited.


    To estimate associations between efavirenz use and depression and suicidal ideation among PLHIV in Uganda.


    Prospective observational cohort study. (ClinicalTrials.gov: NCT01596322)


    Mbarara, Uganda.


    Adult PLHIV enrolled at the start of antiretroviral therapy (ART) and observed every 3 to 4 months from 2005 to 2015.


    The exposure of interest was time-varying efavirenz use, defined as use during the 7 days and in 60 or more of the 90 days before a study visit, compared with nevirapine use. Self-reported outcomes were depression, defined as a mean score greater than 1.75 on the Hopkins Symptom Checklist depression subscale, and suicidal ideation. Multivariable-adjusted generalized estimating equations (GEE) logistic regression, Cox proportional hazards regression, and marginal structural models were fit to estimate the association between efavirenz use and the risk for depression and suicidal ideation.


    694 participants (median age, 33 years; median pretreatment CD4+ count, 1.8 × 109 cells/L) contributed 1200 person-years of observation (460 person-years receiving efavirenz). No baseline differences in depression or suicidal ideation were found between patients ever exposed to efavirenz and those never exposed to efavirenz and receiving nevirapine (P > 0.80 for both). Of 305 participants ever-exposed to efavirenz, 61 (20.0%) and 19 (6.2%) had depression and suicidal ideation, respectively, on at least 1 follow-up visit, compared with 125 (32.1%) and 47 (12.1%) of the 389 who received nevirapine. In adjusted GEE models, efavirenz use was associated with decreased odds of depression compared with nevirapine use (adjusted odds ratio, 0.62 [95% CI, 0.40 to 0.96]) and was not significantly associated with suicidal ideation (adjusted odds ratio, 0.61 [CI, 0.30 to 1.25]). Time-to-event and marginal structural models yielded similar estimates.


    Nonrandom assignment to treatment and substantial differences between the efavirenz and nevirapine groups.


    No evidence was found that use of efavirenz in first-line ART increased the risk for depression or suicidal ideation compared with nevirapine use among PLHIV in Uganda.

    Primary Funding Source:

    National Institutes of Health.


    • 1. Nelson LJBeusenberg MHabiyambere VShaffer NVitoria MAMontero RGet alAdoption of national recommendations related to use of antiretroviral therapy before and shortly following the launch of the 2013 WHO consolidated guidelines. AIDS2014;28 Suppl 2:S217-24. [PMID: 24849481] doi:10.1097/QAD.0000000000000239 CrossrefMedlineGoogle Scholar
    • 2. Mollan KRSmurzynski MEron JJDaar ESCampbell TBSax PEet alAssociation between efavirenz as initial therapy for HIV-1 infection and increased risk for suicidal ideation or attempted or completed suicide: an analysis of trial data. Ann Intern Med2014;161:1-10. [PMID: 24979445]. doi:10.7326/M14-0293 LinkGoogle Scholar
    • 3. Kenedi CAGoforth HWA systematic review of the psychiatric side-effects of efavirenz. AIDS Behav2011;15:1803-18. [PMID: 21484283] doi:10.1007/s10461-011-9939-5 CrossrefMedlineGoogle Scholar
    • 4. Nkhoma ETCoumbis JFarr AMJohnston SSChu BCRosenblatt LCet alNo evidence of an association between efavirenz exposure and suicidality among HIV patients initiating antiretroviral therapy in a retrospective cohort study of real world data. Medicine (Baltimore)2016;95:e2480. [PMID: 26817882] doi:10.1097/MD.0000000000002480 CrossrefMedlineGoogle Scholar
    • 5. Napoli AAWood JJCoumbis JJSoitkar AMSeekins DWTilson HHNo evident association between efavirenz use and suicidality was identified from a disproportionality analysis using the FAERS database. J Int AIDS Soc2014;17:19214. [PMID: 25192857] doi:10.7448/IAS.17.1.19214 CrossrefMedlineGoogle Scholar
    • 6. Smith CRyom LMonforte AdReiss PMocroft AEl-Sadr Wet alLack of association between use of efavirenz and death from suicide: evidence from the D:A:D study. J Int AIDS Soc2014;17:19512. [PMID: 25394021] doi:10.7448/IAS.17.4.19512 CrossrefMedlineGoogle Scholar
    • 7. Bengtson AMPence BWMollan KREdwards JKMoore RDO'Cleirigh Cet alThe relationship between efavirenz as initial antiretroviral therapy and suicidal thoughts among HIV-infected adults in routine care. J Acquir Immune Defic Syndr2017;76:402-8. [PMID: 28749824] doi:10.1097/QAI.0000000000001510 CrossrefMedlineGoogle Scholar
    • 8. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents Living with HIV. Department of Health and Human Services. Accessed at www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf on 19 May 2018. Google Scholar
    • 9. World Health OrganizationConsolidated Guidelines on the Use of Antiretroviral Drugs for Treating and Preventing HIV Infection: Recommendations for a Public Health Approach. Geneva: World Health Organization; 2016. Google Scholar
    • 10. UNAIDS. Global AIDS Update 2016. Geneva: World Health Organization; 2016. Accessed at www.unaids.org/sites/default/files/media_asset/UNAIDS_Gap_report_en.pdf on 19 May 2018. Google Scholar
    • 11. Tsai ACReliability and validity of depression assessment among persons with HIV in sub-Saharan Africa: systematic review and meta-analysis. J Acquir Immune Defic Syndr2014;66:503-11. [PMID: 24853307] doi:10.1097/QAI.0000000000000210 CrossrefMedlineGoogle Scholar
    • 12. Tsai ACWeiser SDPetersen MLRagland KKushel MBBangsberg DRA marginal structural model to estimate the causal effect of antidepressant medication treatment on viral suppression among homeless and marginally housed persons with HIV. Arch Gen Psychiatry2010;67:1282-90. [PMID: 21135328] doi:10.1001/archgenpsychiatry.2010.160 CrossrefMedlineGoogle Scholar
    • 13. Todd JVCole SRPence BWLesko CRBacchetti PCohen MHet alEffects of antiretroviral therapy and depressive symptoms on all-cause mortality among HIV-infected women. Am J Epidemiol2017;185:869-78. [PMID: 28430844] doi:10.1093/aje/kww192 CrossrefMedlineGoogle Scholar
    • 14. Tsai ACWeiser SDSteward WTMukiibi NFKawuma AKembabazi Aet alEvidence for the reliability and validity of the internalized AIDS-related stigma scale in rural Uganda. AIDS Behav2013;17:427-33. [PMID: 22869104] doi:10.1007/s10461-012-0281-3 CrossrefMedlineGoogle Scholar
    • 15. Kaida AMatthews LTAshaba STsai ACKanters SRobak Met alDepression during pregnancy and the postpartum among HIV-infected women on antiretroviral therapy in Uganda. J Acquir Immune Defic Syndr2014;67 Suppl 4:S179-87. [PMID: 25436816] doi:10.1097/QAI.0000000000000370 CrossrefMedlineGoogle Scholar
    • 16. Martinez PAndia IEmenyonu NHahn JAHauff EPepper Let alAlcohol use, depressive symptoms and the receipt of anti-retroviral therapy in southwest Uganda. AIDS Behav2008;12:605-12. [PMID: 17968651] CrossrefMedlineGoogle Scholar
    • 17. Tsai ACBangsberg DRFrongillo EAHunt PWMuzoora CMartin JNet alFood insecurity, depression and the modifying role of social support among people living with HIV/AIDS in rural Uganda. Soc Sci Med2012;74:2012-9. [PMID: 22513248] doi:10.1016/j.socscimed.2012.02.033 CrossrefMedlineGoogle Scholar
    • 18. Ashaba SKakuhikire BVorechovská DPerkins JMCooper-Vince CEMaling Set alReliability, validity, and factor structure of the Hopkins symptom checklist-25: population-based study of persons living with HIV in rural uganda. AIDS Behav2018;22:1467-74. [PMID: 28667469] doi:10.1007/s10461-017-1843-1 CrossrefMedlineGoogle Scholar
    • 19. Bolton PNdogoni LCross-Cultural Assessment of Trauma-Related Mental Illness. Baltimore: Johns Hopkins Univ Pr; 2000. Google Scholar
    • 20. Derogatis LRLipman RSRickels KUhlenhuth EHCovi LThe Hopkins symptom checklist (HSCL): a self-report symptom inventory. Behav Sci1974;19:1-15. [PMID: 4808738] CrossrefMedlineGoogle Scholar
    • 21. Filmer DPritchett LHEstimating wealth effects without expenditure data—or tears: an application to educational enrollments in states of India. Demography2001;38:115-32. [PMID: 11227840] MedlineGoogle Scholar
    • 22. Wu AWRubin HRMathews WCWare JEBrysk LTHardy WDet alA health status questionnaire using 30 items from the Medical Outcomes Study. Preliminary validation in persons with early HIV infection. Med Care1991;29:786-98. [PMID: 1875745] CrossrefMedlineGoogle Scholar
    • 23. Bush KKivlahan DRMcDonell MBFihn SDBradley KAThe AUDIT alcohol consumption questions (AUDIT-c): an effective brief screening test for problem drinking. Ambulatory Care Quality Improvement Project (ACQUIP). Alcohol Use Disorders Identification Test. Arch Intern Med1998;158:1789-95. [PMID: 9738608] CrossrefMedlineGoogle Scholar
    • 24. Fumaz CRMuñoz-Moreno JAMoltó JNegredo EFerrer MJSirera Get alLong-term neuropsychiatric disorders on efavirenz-based approaches: quality of life, psychologic issues, and adherence. J Acquir Immune Defic Syndr2005;38:560-5. [PMID: 15793366] CrossrefMedlineGoogle Scholar
    • 25. VanderWeele TJDing PSensitivity analysis in observational research: introducing the E-value. Ann Intern Med2017;167:268-74. [PMID: 28693043]. doi:10.7326/M16-2607 LinkGoogle Scholar
    • 26. Gross RBellamy SLRatshaa BHan XVujkovic MAplenc Ret al CYP2B6 genotypes and early efavirenz-based HIV treatment outcomes in Botswana. AIDS2017;31:2107-13. [PMID: 28692529] doi:10.1097/QAD.0000000000001593 CrossrefMedlineGoogle Scholar
    • 27. Rotger MColombo SFurrer HBleiber GBuclin TLee BLet alSwiss HIV Cohort StudyInfluence of CYP2B6 polymorphism on plasma and intracellular concentrations and toxicity of efavirenz and nevirapine in HIV-infected patients. Pharmacogenet Genomics2005;15:1-5. [PMID: 15864119] CrossrefMedlineGoogle Scholar
    • 28. Haas DWRibaudo HJKim RBTierney CWilkinson GRGulick RMet alPharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study. AIDS2004;18:2391-400. [PMID: 15622315] MedlineGoogle Scholar
    • 29. Mukonzo JKOkwera ANakasujja NLuzze HSebuwufu DOgwal-Okeng Jet alInfluence of efavirenz pharmacokinetics and pharmacogenetics on neuropsychological disorders in Ugandan HIV-positive patients with or without tuberculosis: a prospective cohort study. BMC Infect Dis2013;13:261. [PMID: 23734829] doi:10.1186/1471-2334-13-261 CrossrefMedlineGoogle Scholar
    • 30. Sarfo FSZhang YEgan DTetteh LAPhillips RBedu-Addo Get alPharmacogenetic associations with plasma efavirenz concentrations and clinical correlates in a retrospective cohort of Ghanaian HIV-infected patients. J Antimicrob Chemother2014;69:491-9. [PMID: 24080498] doi:10.1093/jac/dkt372 CrossrefMedlineGoogle Scholar
    • 31. Ribaudo HJLiu HSchwab MSchaeffeler EEichelbaum MMotsinger-Reif AAet alEffect of CYP2B6, ABCB1, and CYP3A5 polymorphisms on efavirenz pharmacokinetics and treatment response: an AIDS Clinical Trials Group study. J Infect Dis2010;202:717-22. [PMID: 20662624] doi:10.1086/655470 CrossrefMedlineGoogle Scholar
    • 32. Gatch MBKozlenkov AHuang RQYang WNguyen JDGonzález-Maeso Jet alThe HIV antiretroviral drug efavirenz has LSD-like properties. Neuropsychopharmacology2013;38:2373-84. [PMID: 23702798] doi:10.1038/npp.2013.135 CrossrefMedlineGoogle Scholar
    • 33. Huang RChen ZDolan SSchetz JADillon GHThe dual modulatory effects of efavirenz on GABAA receptors are mediated via two distinct sites. Neuropharmacology2017;121:167-78. [PMID: 28456686] doi:10.1016/j.neuropharm.2017.04.038 CrossrefMedlineGoogle Scholar
    • 34. Ford NShubber ZPozniak AVitoria MDoherty MKirby Cet alComparative safety and neuropsychiatric adverse events associated with efavirenz use in first-line antiretroviral therapy: a systematic review and meta-analysis of randomized trials. J Acquir Immune Defic Syndr2015;69:422-9. [PMID: 25850607] doi:10.1097/QAI.0000000000000606 CrossrefMedlineGoogle Scholar
    • 35. Journot VChene GDeCastro NRancinan CCassuto JPAllard Cet alALIZE Study GroupUse of efavirenz is not associated with a higher risk of depressive disorders: a substudy of the randomized clinical trial ALIZE-ANRS 099. Clin Infect Dis2006;42:1790-9. [PMID: 16705588] CrossrefMedlineGoogle Scholar
    • 36. Poupard MNgomGueye NFThiam DNdiaye BGirard PMDelaporte Eet alQuality of life and depression among HIV-infected patients receiving efavirenz- or protease inhibitor-based therapy in Senegal. HIV Med2007;8:92-5. [PMID: 17352765] CrossrefMedlineGoogle Scholar
    • 37. Venter WDFClayden PSerenata COPTIMIZE ConsortiumThe ADVANCE study: a groundbreaking trial to evaluate a candidate universal antiretroviral regimen. Curr Opin HIV AIDS2017;12:351-4. [PMID: 28538284] doi:10.1097/COH.0000000000000389 CrossrefMedlineGoogle Scholar
    • 38. Kalichman SCSimbayi LCCloete AMthembu PPMkhonta RNGinindza TMeasuring AIDS stigmas in people living with HIV/AIDS: the internalized AIDS-related stigma scale. AIDS Care2009;21:87-93. [PMID: 19085224] doi:10.1080/09540120802032627 CrossrefMedlineGoogle Scholar